Early Real-World First-Line Treatment With Venetoclax Plus HMAs Versus HMA Monotherapy Among Patients With AML in a Predominately US Community Setting

By sjmartinez • March 17, 2023

Gershon A, Ma E, Xu T, Montez M, Naqvi K, Ku G, Cheng WW, Flahavan EM, Kota V, Greenwald DR. Early Real-World First-Line Treatment With Venetoclax Plus HMAs Versus HMA Monotherapy Among Patients With AML in a Predominately US Community Setting. Clin Lymphoma Myeloma Leuk. 2023 Feb 11:S2152-2650(23)00037-X. doi: 10.1016/j.clml.2023.02.002. Epub ahead of print. PMID: 36925388.

Tags: Acute myeloid leukemia, Azacitidine, Decitabine, Hematology/Oncology, Outcomes research, Publications, Real-word data

Feasibility of frequent monitoring of symptoms using the PRO-CTCAE in the NRG-BR004 clinical trial

Bandos H, Kim S, Henry NL, Hays RD, Calsavara VF, Luu M, Gresham G, Lu KY, Irvin WJ, Suga JM, Siddique S, Cecchini RS, Rogatko[...]

CD19 Expression in B-Cell Lymphomas and Clinical Considerations in the Evolving Landscape of CD19-Targeted Therapy

Marshalek JP, Qing X, Tomassetti S. CD19 Expression in B-Cell Lymphomas and Clinical Considerations in the Evolving Landscape of CD19-Targeted Therapy. World J Oncol. 2025[...]

Phase Ib/II trial of talimogene laherparepvec alone and with pembrolizumab in advanced solid tumors with liver metastases and hepatocellular carcinoma

Hecht JR, Oberoi A, Garralda Cabanas E, Jae Chon H, Digklia A, Rottey S, Martin Jimenez M, Chaney M, Hippenmeyer J, Lawrence T, Liu K,[...]